Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07527078 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Primary completion moved earlier from Apr 10, 2027 to Apr 7, 2026 · Site details revisedv2 Show 2 more changesShow less
    • Primary completion moved earlier from Apr 10, 2027 to Apr 7, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate the efficacy of GZR33 Injection and Insulin Degludec Injection (Tresiba®) in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs.
Trial Details
NCT Number NCT07527078
Lead Sponsor Gan & Lee Pharmaceuticals.
Conditions Type 2 Diabetes (T2DM)
Enrollment 350 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov